ENY Antibody
Description
Search Methodology
-
Database review: Examined major antibody databases including the Antibody Registry ( ), AbDb ( ), and PLAbDab ( ), which collectively catalog over 500,000 antibodies.
-
Literature analysis: Scanned 13 peer-reviewed articles and technical guides related to antibody research ( ).
-
Commercial sources: Checked leading antibody vendors such as Abcam ( ) and Kyowa Kirin ( ).
No entries matching "ENY Antibody" were identified in these resources.
Terminology Issues
-
Typographical error: The term may refer to a misspelled antibody (e.g., "ENA Antibody" [Extractable Nuclear Antigen], a well-characterized autoantibody panel used in autoimmune diagnostics ).
-
Nomenclature ambiguity: Could represent an internal project name, unpublished reagent, or non-standard abbreviation not widely adopted by the scientific community.
Research Status
-
If "ENY Antibody" is a novel compound, it may not yet be published or deposited in public databases. Over 30% of antibodies described in patents lack public characterization data ( ).
Recommendations for Further Investigation
-
Verify terminology: Confirm the exact spelling and context of "ENY" with the original source.
-
Explore specialized repositories:
-
Screen patent databases: Over 75% of antibody sequences in PLAbDab originate from patents ( ).
Antibody Validation Considerations
If pursuing novel antibody development, adhere to best practices to avoid reproducibility issues:
| Validation Step | Key Metrics | References |
|---|---|---|
| Target specificity | Knockout cell line controls | |
| Application compatibility | Western blot, immunofluorescence | |
| Batch-to-batch consistency | Recombinant antibody platforms |
Related Antibody Classes
For context, below are well-characterized antibody types frequently studied:
| Antibody Type | Function | Clinical Relevance |
|---|---|---|
| IgG | Neutralizes pathogens in serum | Autoimmunity, therapeutics |
| IgM | Early immune response activator | Infectious disease diagnosis |
| IgA | Mucosal immunity | Gastrointestinal protection |
| IgE | Allergic response mediation | Hypersensitivity disorders |
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- The physical interaction of ENY with DELLAs, along with an ENY-triggered accumulation of DELLA transcripts during maturation, supports the notion that ENY mediates gibberellin effects to balance abscisic acid-promoted maturation during late seed development. PMID: 21571950
